Paris, France, April 17, 2023, 7:00 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.24-0299.

The universal registration document notably includes:

  • the 2023 annual financial report;
  • the management report;
  • the report on corporate governance; and
  • the description of the share buyback program.

This universal registration document may be consulted on the Company’s website (, “Investors” section, and on the AMF’s website (